|
614-893-0910 or BTCarroll1@cs.com - 614-937-9427
|
|
|
Brendan T. Carroll, M.D.
Associate Professor of Psychiatry*, University of Cincinnati and
Acting Chief of Psychiatry, Chillicothe VAMC, Chillicothe, Ohio
Brendan T. Carroll, MD, is The Acting Chief of the Psychiatry Service at the Chillicothe VAMC in Chillicothe, Ohio where he oversees inpatient and outpatient services for over 3,000 patients/veterans. He is also Associate Professor of Psychiatry (Volunteer) at the University of Cincinnati in Cincinnati, Ohio.
He graduated from Bishop Ready High School in Columbus, Ohio. After earning his Bachelor of Science degree from St. Joseph's University in Philadelphia, Pennsylvania, Dr. Carroll obtained his Medical Degree at the Medical College of Ohio in Toledo, Ohio. He completed a residency in psychiatry at the University of Iowa in Iowa City, Iowa. He is board certified in Psychiatry with additional qualifications in Forensic Psychiatry.
Dr. Carroll is a member of The Movement Disorder Society and was awarded the Outstanding Service Award from the Neuroleptic Malignant Syndrome Information Service. His major research interests include: Catatonia, neuroleptic malignant syndrome, schizophrenia and bipolar disorder. In addition to lecturing in numerous national and international meetings, Dr. Carroll has published his research in such prestigious journals as the American Journal of Psychiatry, Neuropsychiatry and Clinical Neurosciences and CNS Spectrums.
He is the co-founder of The Neuroscience Alliance. He is an author of 2 chapters for the book Catatonia: From Psychopathology to Neurobiology (2004). His hobbies include: Fly-fishing, hiking, snowboarding and skiing with his wife and family.
Dr Carroll is on Speaker's Bureau and Key opinon leader for: Abbott Laboratories, GlaxoSmithKline (Glaxo Wellcome), Eli Lilly and Company, Pfizer, Janssen, Astra Zeneca, & Bristol-Myers Squibb.
|
Christopher Thomas Pharm.D., BCPP, FASCP
Clinical Pharmacy Specialist in Psychiatry
Chillicothe VAMC
Psychopharmacy Consultant Omnicare Inc. Adjunct Associate Professor of Pharmacy Practice Butler University College of Pharmacy and Health Sciences Adjunct Associate Professor of Pharmacy Practice University of Toledo College of Pharmacy
Dr. Thomas is the clinical pharmacist for the inpatient psychiatric wards at the Chillicothe VAMC. He is also the psychopharmacy consult liaison for Omnicare Inc, a pharmacy that services long-term care facilities. He also has academic affiliations with Butler University and University of Toledo and precepts students from Ohio Northern University and Ohio State University.
Chris was born in Greenfield, IN and completed high school at Greenfield Central High School. After high school, he attended and graduated from Butler University with his Doctor of Pharmacy Degree. Chris then completed a specialty pharmacy practice residency in psychopharmacology/psychiatric pharmacy practice at the Cleveland VAMC. In 2003, he was acknowledged as a board certified psychiatric pharmacist (BCPP).
Chris is an active member in the following pharmacy organizations: College of Psychiatric and Neurologic Pharmacists, American Society of Consultant Pharmacists, American Society of Health System Pharmacy, American College of Clinical Pharmacy, and Ohio College of Clinical Pharmacy. In 2003, Chris was recognized as a Fellow of the American Society of Consultant Pharmacy.
Chris' research interests include the role of norepinephrine in agitation, aggression, and anxiety disorders, metabolic adverse events with the second-generation antipsychotics, pharmacoeconomics and health outcomes with antidepressants and second-generation antipsychotics. His hobbies include swimming, tennis, automobiles, art appreciation, theater, and shopping (with his wife).
Chris has lectured over 100 times on his research interests in the midwest to various health care professionals, residents and students. Chris is proud to be on the Brain Trust for the Neuroscience Alliance
|
Harold W. Goforth, M.D.
Fellow, Division of Geriatric Psychiatry, Duke University Medical Center, Durham, NC.
Harold W. Goforth, M.D. currently serves as a Fellow in the Division of Geriatric Psychiatry, Department of Psychiatry, Duke University Medical Center, Durham, NC.
Dr. Goforth graduated from Clyde A. Erwin High School in Asheville, NC. After earning his Bachelor of Arts degree from North Carolina State University, Raleigh, NC, he obtained a Master of Arts degree from The Ohio State University, Columbus, OH, and obtained his medical degree from Wright State University, Dayton, OH. Dr. Goforth subsequently completed single years of training in General Surgery and Anatomic Pathology at Northwestern University Medical Center and the University of Chicago Medical Centers respectively. Dr. Goforth completed a residency in general adult psychiatry at Loyola University Medical Center, Maywood, IL, in June 2004, and entered a fellowship training program in geriatric psychiatry at Duke University Medical Center, Durham, NC in July 2004. Dr. Goforth is currently board eligible in Adult Psychiatry.
Dr. Goforth is a member of various professional organizations including the American Association for Geriatric Psychiatry, American Neuropsychiatric Association, Psychosomatics Association, and the EEG and Clinical Neuroscience Society (ECNS). His major research interests include dementia, cerebrovascular disease and associated mood and cognitive deficits, electroencephalography, pain control, and psychotic states. Dr. Goforth has published letters, original research, reviews, and book chapters in various journals including the Journal of Clinical Psychopharmacology, Australian and New Zealand Journal of Psychiatry, Current Psychiatry, Clinical EEG, and Addictive Disorders and Their Treatment. He has also co-authored two book chapters regarding catatonia.
|
John M. Hawkins, M.D.
Volunteer Assistant Clinical Professor of Psychiatry, University of Cincinnati and Staff Psychiatrist, Central Clinic, Cincinnati, Ohio
Dr. Hawkins received his medical degree from the Medical College of Wisconsin in 1991. He completed his residency in General Psychiatry at the University of Cincinnati in 1995, where he also completed a fellowship in Biological Psychiatry in 1996.
From 1996 until 1998, he was the Director of the Inpatient Research Unit while an Assistant Professor of Psychiatry at UC. He conducted both inpatient and outpatient clinical trials and co-authored several journal articles. Research interests included new onset psychosis, Bipolar Disorder, catatonia and anatomical and functional imaging studies of the brain.
Since 1998, he has been in Private Practice. Additionally, he is a Staff Psychiatrist at the University affiliated community mental health outpatient clinic, where he is also involved in residency training, supervising psychiatric residents in their 3rd. year of training. He is also on the Speaker's Bureau of several pharmaceutical companies.
He has received several awards, including a Golden Apple Teaching Award for medical student teaching and the NAMI National Exemplary Psychiatrist Award in 2004.
|
|
TBA
|
MARK J. WOYSHVILLE, M.D. FAASM
Brief Bio
Dr. Woyshville is board-certified in Psychiatry and Sleep Medicine. In addition to the private practice of psychiatry he is CEO and Medical Director of North Star Medical Research LLC in Cleveland, Ohio, performing all phases of therapeutics development, with a focus on neuropsychiatry.
Dr. Woyshville attended the University of Cincinnati College of Medicine, graduating in 1989. He then served an internship at the Cleveland Clinic Foundation before taking up psychiatric residency at the University of California, San Diego. He was then the first Mood Disorders Special Fellow with the Mood Disorders division of the Department of Psychiatry at Case-Western Reserve University, following which he served as an assistant professor of psychiatry for five years. During his tenure at Case, Dr. Woyshville established the Clinical Drug Trials Unit within Mood Disorders, was the attending physician for the inpatient and outpatient ECT services, as well as being attending on an inpatient Mood Disorders specialty unit and a partial hospitalization program.
Dr. Woyshville has also served as a psychiatrist in a variety of institutional settings, such as the Veteran’s Administration Recovery Center, working with the dually-diagnosed; as a forensic psychiatrist in both a state hospital and prison setting; and as staff psychiatrist with a large mental health center in Lorain, Ohio.
Dr. Woyshville became involved with sleep clinical practice and research in collaboration with the Southwest Cleveland Sleep Center, which eventuated in the formation of the Cleveland Neuro-Sleep Research Institute, Inc. He carried out a clinical practice focusing on difficult-to-treat sleep disorders in a neuropsychiatric patient population, as well as engaging in clinical research, likewise focused on neuropsychiatry. He has most recently started his own research venue, North Star Medical Research LLC, and continues in the private practice of psychiatry. He resides in North Royalton, Ohio, with his wife Veronica, son Aaron (age 13) and daughter Colette (age 8).
Curriculum Vitae
MARK J. WOYSHVILLE, M.D. FAASM
18660 Bagley Road
Building I Suite 204
Middleburg Heights, OH 44130
Voice: (440) 243-9977
Fax: (440) 243-9997
mjw14@sbcglobal.net
CURRENT LICENSES, CERTIFICATIONS AND REGISTRATIONS
9/21/05 Diplomate, American Board of Sleep Medicine
6/19/95 Diplomate (Psychiatry), American Board of Psychiatry and Neurology
Recertified September 7, 2005
2/14/92 State of Ohio, Medicine and Surgery Certificate, #35-06-3012
12/3/90 Drug Enforcement Administration, registration, practitioner, all schedules
7/1/90 Diplomate, National Board of Medical Examiners
POSTGRADUATE TRAINING AND ACADEMIC ACTIVITY
7/93-7/98 Case Western Reserve University
Assistant Professor of Psychiatry
7/92-6/93 Case Western Reserve University/University Hospitals of Cleveland
Mood Disorders Special Fellow
7/90-6/92 University of California, San Diego (UCSD), La Jolla, California
Psychiatric residency
7/89-6/90 Cleveland Clinic Foundation, Cleveland, Ohio.
Combined internship in psychiatry, medicine, and neurology
EDUCATION
9/85-6/89 University of Cincinnati College of Medicine, Cincinnati, Ohio
M.D. awarded 6/89
1/84-6/85 University of California, San Diego, La Jolla, California
Post-baccalaureate work in chemistry, biology, and mathematics
9/76-6/82 Cleveland State University, Cleveland, Ohio
B.S. (Physics), awarded Magna Cum Laude, 6/82
CLINICAL, ADMINISTRATIVE, AND SUPERVISORY ACTIVITY
4/07 to CEO and Medical Director
present
North Star Medical Research is engaged in research at all levels of therapeutics development, including proof-of-concept and investigator-initiated studies. Our primary emphasis is on neuropsychiatry.
1/06 to Cleveland Neuro-Sleep Research Institute, Inc.
4/07 Medical Director
The Institute was engaged in research involving sleep and neuropsychiatry, as well as rheumatologic, endocrine, and cardiovascular conditions, among others.
7/01 to Co-Director, Southwest Cleveland Sleep Center
4/07 Director, Neuropsychiatric Sleep Medicine Program
The Center’s mission focuses on the evaluation and management of sleep disorders of all kinds, with an emphasis on comorbid sleep and neuropsychopathology. Programs in education and research are ongoing.
7/00 to Member, Disability Evaluators Panel, Ohio Bureau of Workers’ Compensation
present Specialist Examiner, Industrial Commission of Ohio
As a Panel member, I provide impartial and thorough independent medical evaluations bearing on the issues of causality and impairment related to industrial injury claims.
10/97 to Private Practice of General Psychiatry
present
This independent, self-pay practice provides consultation, evaluation, and management services to individuals and organizations; specialization is in the psychodynamic and psychopharmacologic treatment of clergy, religious, and secular professionals.
1/00–6/01 Psychiatrist, Ohio Department of Rehabilitation and Corrections
7/04–7/05
I served as an attending psychiatrist treating the seriously and persistently mentally ill in a State custody facility; and the dually-diagnosed mentally ill in a privately-contracted State custody setting.
6/01–4/04 Forensic Psychiatrist, Ohio Department of Mental Health
As the Attending Psychiatrist on an inpatient Restoration to Competency unit, I provided clinical care, forensic evaluations, and expert testimony.
5/00–2/01 Psychiatrist, Family Focus Center
I served as an attending psychiatrist, treating mentally ill children and adolescents in a community mental health setting.
11/98–1/00 Psychiatrist, W.G. Nord Center
As an attending psychiatrist at a large, urban community mental health center, I provided the full spectrum of psychiatric services, with an emphasis on treating the seriously and persistently mentally ill.
3/97-9/97 Attending Psychiatrist, Veteran’s Addictions Recovery Center, VAMC
My responsibilities included providing the full spectrum inpatient and outpatient dual-diagnosis assessment and management. Specialized in the treatment of veterans suffering with substance use disorders in the context of severe mental illness. 70% effort.
3/97–9/97 Research Psychiatrist, Veteran’s Addictions Recovery Center, VAMC
I participated in research quantifying affect in dually diagnosed (addictive disorder plus other mental illness) veterans with “high negative affect,” using the measures and methods of chaos theory. 30% effort.
7/93-3/97 Assistant Professor of Psychiatry, Case-Western Reserve University:
I provided teaching and supervision in psychopharmacologic and psychodynamic psychiatry for residents individually and as a class; I initiated and conducted the Psychodynamic Psychiatry Seminar series; and I performed pre-clinical and clinical medical student teaching. As the Director of the Clinical Drug Trials Unit of the Mood Disorders Program, I provided all Director services to the six research personnel (one fiscal administrator, one clinical administrator, and four research assistants) in the Mood Disorders Research Program; I led and directed weekly consensus and inter-rater reliability meetings; I was responsible for nurturing the research culture of the Program.
I was the founding physician of the Partial Hospitalization Program and its first full-time, regular attending. I worked closely with administration to support and direct the growth of the Program, while supervising and teaching all disciplines. As an attending on the Hanna Pavilion 4 Adult Inpatient Psychiatric Unit, I was responsible for providing attending leadership for an inpatient interdisciplinary team, treating the full spectrum of adult psychopathology emphasizing mood disorders, schizophrenia, and borderline personality disorder. I also provided inpatient and outpatient ECT services, as well as supervising and teaching all disciplines.
FELLOWSHIPS, ELECTIVES, AWARDS, SPECIAL QUALIFICATIONS
7/95 Special Dedication Award for teaching, presented by Case Western Reserve psychiatric residents
7/92-6/93 Mood Disorders Research Fellow with special emphasis on the management of treatment-resistant affective disorders utilizing psychopharmacology and electroconvulsive therapy.
3/89-5/89 Clinical Research Elective in “Computers in Clinical Medicine”.
National Institutes of Health, Bethesda, Maryland.
6/86-9/86 Dean’s Office Summer Research Fellowships, $1,200.00 each.
6/85-9/85 University of Cincinnati College of Medicine
ACADEMIC RESEARCH
Peer Reviewed Research:
7/94-7/98 Case Western Reserve University/University Hospitals of Cleveland
Principal Investigator, "Affective Instability: Quantification, Conceptualization, and Clinical Significance."
Funding: National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award, $60,000.
3/95-9/96 Case Western Reserve University/University Hospitals of Cleveland
Mood Disorders Program
Co-Investigator in a maintenance study comparing valproate and lithium in bipolar rapid cycling.
Funding: National Institute of Mental Health; The Stanley Foundation.
Unrestricted Educational Grants:
7/96-7/98 Case Western Reserve University/University Hospitals of Cleveland
Recipient, Wyeth-Ayerst Unrestricted Educational Grant, in support of theoretical and phenomenological work in affective disorders. $24,000.
Investigator-Initiated Research:
North Star Medical Research LLC:
A double-blind, placebo-controlled randomized clinical trial (RCT) of a dopamine agonist in the management of restless legs syndrome (RLS) in patients treated with serotonergically-active antidepressants; awarded.
Industry Sponsored Research:
Cleveland Neuro-Sleep Research Institute, Inc.:
A phase III pivotal, multi-center, double-blind, randomized, placebo-controlled mono-therapy study of milnacipran for treatment of fibromyalgia.
A long-term study of XP13512 vs. placebo treatment assessing maintenance of efficacy and safety in patients with restless legs syndrome.
A comparison of zolpidem tartrate extended-release vs. placebo in the treatment of insomnia associated with newly diagnosed major depressive disorder (MDD) or untreated MDD relapse, when used concomitantly with escitalopram.
A comparison of zolpidem tartrate extended-release vs. placebo in the treatment of insomnia associated with generalized anxiety disorder (GAD) when used concomitantly with escitalopram.
A 28 day, polysomnographic and subjective assessment of GW679769, 10 and 30 mg, for the treatment of primary insomnia: A randomized, double-blind, parallel-group, placebo-controlled trial.
A 52-Week, open-label study to assess the long-term safety of ropinirole extended release (XR) in patients with restless legs syndrome (RLS).
Southwest Cleveland Sleep Center:
A phase 2, double-blind, randomized, placebo-controlled, parallel-group, multicenter, proof-of-concept study to evaluate the safety and efficacy of Rozerem ™ taken in combination with gabapentin for the treatment of subjects with chronic insomnia.
A randomized, double-blind, placebo-controlled, 3-way cross-over study to evaluate effects of APD125 in patients with insomnia.
A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to assess the long term efficacy and safety of doxepin HCl in primary elderly insomnia patients with sleep maintenance difficulties.
Efficacy and safety of eplivanserin 5 mg/day on sleep maintenance insomnia: a 12-week multicenter, randomized, double-blind, placebo-controlled study followed by an open treatment phase extension with eplivanserin for 40 weeks period.
The efficacy of eszopiclone 3 mg as adjunctive therapy in subjects with insomnia related to generalized anxiety disorder (GAD).
A double-blind, randomized, placebo-controlled, multicenter, 30-night polysomnographic study of MK-0928 in adult patients with insomnia.
A double-blind, randomized, placebo-controlled, multicenter, 30-night polysomnographic study of MK-0928 in elderly patients with insomnia.
A 12 week, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of Ropinirole XR (extended release) in patients with restless legs syndrome.
Randomized, double-blind, positive-controlled, multicenter study comparing the efficacy of carvedilol phosphate modified release formulation (Coreg™ MR) and metoprolol succinate extended release (Toprol-XL®) on the reduction of microalbuminuria in patients with hypertension and microalbuminuria.
A 12 month open-label, flexible-dosage (100-250 mg/day) extension study of the safety and efficacy of cep-10953 in the treatment of patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, or chronic shift work sleep disorder.
Randomized, double-blind, placebo-controlled, parallel-group, multi-center trial comparing the effects of orally administered Xyrem (sodium oxybate) with placebo for the treatment of fibromyalgia.
A 12-week, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of cep-10953 (150 mg/day) as treatment for adults with residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome.
Randomized, double-blind, placebo controlled, parallel-group, multi-center trial comparing the effects of orally administered Xyrem ® (sodium oxybate) with placebo for the treatment of narcolepsy.
Randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multi-center trial comparing the effects of orally administered Xyrem (sodium oxybate) with modafinil with placebo for the treatment of daytime sleepiness in narcolepsy.
Case Western Reserve University/University Hospitals of Cleveland Mood Disorders Program:
A study investigating the antimanic efficacy of the anticonvulsant gabapentin (Neurontin), which is thought to act by blocking the uptake of GABA by the neuroglia and by inhibiting the synthesis of excitatory amino acids.
A study comparing the rate of onset of antidepressant action of venlafaxine (Effexor) vs. fluoxetine (Prozac) in major depression.
Clinical trials of lamotrigine (Lamictal), an anticonvulsant which acts by antagonizing sodium channel mediated excitatory neurotransmitter release, in the management of bipolar disorder.
A double-blind, placebo-controlled study of the safety and efficacy of paroxetine (Paxil) vs. imipramine in bipolar depression.
Double-blind maintenance study comparing valproate to lithium and placebo in the treatment of bipolar disorder.
A study evaluating the efficacyy of clozapine (Clozaril) in the treatment of refractory bipolar mood disorder and schizoaffective disorder, bipolar subtype.
A study comparing amesergide, a novel 5-HT type 2 antagonist, to placebo and fluoxetine in the treatment of depression.
Dose-finding study researching roxindole, a novel agent with D-2 autoreceptor and 5-HT type 1A agonist activities, and 5-HT re-uptake blockade action, in comparison with placebo in the treatment of depression.
Pre-doctoral Research:
3/89-5/89 National Institutes of Health, National Library of Medicine,
Artificial Intelligence Branch.
Designed and implemented a utility in Prolog (an artificial intelligence programming language) to facilitate the assignment of Medical Subject Headings to nodes in the National Library of Medicine Semantic Network.
Funding: National Institutes of Health
6/86-5/89 University of Cincinnati College of Medicine
Division of Geriatrics/Alzheimer’s Research Center
Investigated EEG changes in Alzheimer’s dementia using the fractal dimension as a quantifier. Researched the relationship between non-linear metric studies on the EEG and clinical grades of severity in the dementias.
Funding: University of Cincinnati College of Medicine
6/85-5/89 University of Cincinnati College of Medicine
Division of Pharmacology and Cell Biophysics
Researched mathematical models capable of simulating certain aspects of neuronal behavior. This work involved investigations of model nonlinear dynamical systems using analog computers.
Funding: University of Cincinnati College of Medicine
11/84-6/85 University of California, San Diego, School of Medicine.
Laboratory of Biological Dynamics and Theoretical Medicine
Expanded the capabilities of the laboratory to include analog computation for solving nonlinear differential equations by continuous time-domain integration.
Funding: University of California, San Diego, School of Medicine.
PUBLICATIONS
Peer Reviewed Publications:
Woyshville MJ, Lackamp JM, Eisengart JA, Gilliland JAM. On the meaning and measurement of affective instability: Clues from chaos theory. (Original Paper). Biological Psychiatry 1999; 45(3):261-269.
Gordon RT, Cantor RJ, Woyshville MJ. A new chaos-based approach to data conceptualization. (Article) In: Dagli CH, Akay M, Chen CL, Fernandez BR, Ghosh J, eds. Intelligent Engineering Systems Through Artificial Neural Networks, Vol 6, ASME press, New York, 1996.
Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine in treatment refractory mania. (Article). American Journal of Psychiatry 1996;153:759-764.
Calabrese JR, Fatemi SH, Kujawa M, Woyshville MJ. Predictors of differential response to mood stabilizers. (Article). Journal of Clinical Psychopharmacology 1996. 16[2 suppl 1]:24S-31S.
Calabrese JR, Woyshville MJ. Lithium therapy: Limitations and alternatives in the treatment of bipolar disorders. (Article). Annals of Clinical Psychiatry 1995;7(2):103-112.
Calabrese JR, Woyshville MJ. A medication algorithm for treatment of rapid cycling? (Article). Journal of Clinical Psychiatry 1995;5[suppl 3]:11-18.
Kimmel SE, Calabrese JR, Woyshville MJ, Meltzer HY. Clozapine in treatment refractory mood disorders. (Article). Journal of Clinical Psychiatry 1994; 55(supplement B):91-93.
Woyshville MJ, Calabrese JR. Quantification of occipital EEG changes in Alzheimer’s disease utilizing a new metric: The fractal dimension. (Article). Biological Psychiatry 1994; 35(6):381-387.
Calabrese JR, Woyshville MJ, Kimmel SE, and Rapport DJ. Mixed states and bipolar rapid cycling and their treatment with valproate. (Article). Psychiatric Annals 1993; 23(2):70-78.
Calabrese JR, Woyshville MJ, Kimmel SE, and Rapport DJ. Predictors of valproate response in bipolar rapid cycling. (Brief Report). Journal of Clinical Psychopharmacology 1993; 13(4):280-283.
Calabrese JR, Rapport DJ, Kimmel SE, Reece B, and Woyshville MJ. Rapid cycling bipolar disorder and its treatment with valproate. (Article). Canadian Journal of Psychiatry. 1993; 38:45-51.
Abstracts:
Calabrese JR, Woyshville MJ, Bowden C, et al: Spectrum of efficacy of lamotrigine in treatment-refractory manic depression. Presented at the Second International Conference on Affective Disorders. Jerusalem, Israel. September 4-8, 1995
Letters:
Calabrese JR, Fatemi SH, Woyshville MJ: Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. Am J Psychiatry 1996;153(9):1236.
Book Chapters:
Calabrese JR, Bowden CL, McElroy S, Cookson J, Andersen J, Rhodes L, Woyshville MJ, Keck P, Kundu S, Paterson G, Ascher J, Bolden-Watson, C. Efficacy of lamotrigine in bipolar disorders: Preliminary data on the affective disorders. In: Manji H, Bowden C, Belmaker R, eds. Mechanisms Of Antibipolar Disorder Treatments: Focus On Lithium, Valproate, And Carbamazepine. Washington DC: American Psychiatric Press; 1997.
Calabrese JR, Fatemi SH, Woyshville MJ. Diagnosis and treatment of rapid cycling bipolar disorder. In: Dunner DL, ed. Current Psychiatric Therapy II. W.B. Saunders Co. 1997.
Calabrese JR, Bowden C, Woyshville MJ. Lithium and anticonvulsants in bipolar disorder. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. Raven Press, Inc. NY, NY. 1995
Calabrese JR, Woyshville MJ, Rapport DJ. Clinical efficacy of valproate. In: Joffe RT, Calabrese JR, eds. Anticonvulsants in Mood Disorders. Marcel Dekker, Inc. NY, NY. 1994.
CME Publications:
Calabrese JR, Woyshville MJ. Diagnosis and treatment of rapid-cycling bipolar disorder. (Lesson). Directions in Psychiatry 1994; 14(16).
|
|
|
|
 |
|
